source
- Eyepoint's wet AMD therapy misses primary goal in Phase 3, stock tumblesEyepoint reported that its experimental drug Duravyu did not keep vision in patients with wet age-related macular degeneration when given less frequently than the standard of care, causing the Phas…
- Slate Medicines secures $245M financing and Nasdaq listing via reverse merger with Fulcrum TherapeuticsSlate Medicines, a North Carolina biotech, is moving toward a Nasdaq listing through a reverse merger with Fulcrum Therapeutics, six months after emerging from stealth. The transaction includes a…